Holen Sie sich die Stockscreener-App
158.17
1.10%
-1.76
Handel nachbörslich:
158.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$159.93
Offen:
$158.84
24-Stunden-Volumen:
2.09M
Relative Volume:
0.74
Marktkapitalisierung:
$43.58B
Einnahmen:
$21.37B
Nettoeinkommen (Verlust:
$1.41B
KGV:
40.11
EPS:
3.9437
Netto-Cashflow:
$3.07B
1W Leistung:
+4.10%
1M Leistung:
+11.69%
6M Leistung:
-23.63%
1J Leistung:
-12.56%
1-Tages-Spanne:
$157.02
$163.14
1-Wochen-Bereich:
$148.34
$163.14
52-Wochen-Spanne:
$140.11
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
158.17 | 44.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
345.42 | 142.49B | 10.58B | 3.00B | 2.83B | 8.2437 |
ALC
Alcon Inc
|
70.26 | 34.44B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
39.79 | 34.76B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
198.99 | 29.41B | 5.54B | 1.52B | 1.74B | 10.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Goldman | Neutral |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-03 | Fortgesetzt | Citigroup | Buy |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
A3LUHG Bond Profile — Key Metrics - TradingView
Becton Dickinson & Co. stock underperforms Friday when compared to competitors - MarketWatch
Becton Dickinson (BDX) Stock Looks Cheap On Cash Flow Yet Fair On Earnings - simplywall.st
Becton Dickinson & Co (BDX) Shares Surge 3.3% -- What GF Score o - GuruFocus
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Becton Dickinson stock holds steady as medical technology demand underpins long-term growth - ad-hoc-news.de
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BDX.GE Bond Profile — Key Metrics - TradingView
Goldman Sachs Adjusts Price Target on Becton, Dickinson and Company to $152 From $150, Maintains Neutral Rating - Moomoo
US75887CK3 Bond Profile — Key Metrics - TradingView
XS276302639 Bond Profile — Key Metrics - TradingView
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $175 - Moomoo
XS283900436 Bond Profile — Key Metrics - TradingView
Becton, Dickinson and Company (BDX) Stock Analysis: A 16% Upside Opportunity in the Healthcare Sector - DirectorsTalk Interviews
BD Korea expands BD Aptra portfolio with launch of single-use digital flexible cystoscope in Korea - koreabiomed.com
Becton, Dickinson and Company stock: Is BDX underperforming the healthcare sector? - MSN
Evercore Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $180 - 富途牛牛
Becton Dickinson & Co highlights its medical technology footprint as a global healthcare supplier - Ad Hoc News
A Look at Becton Dickinson & Co (BDX) After 3.7% Decline -- GF V - GuruFocus
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton Dickinson (BDX) Following Its Veritor Shift And Index Changes Looks Undervalued - simplywall.st
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom - The Motley Fool
Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance - 富途牛牛
Becton Dickinson and Co steadies operations as healthcare demand evolves - ad-hoc-news.de
Form 4 Becton Dickinson and Co For: 6 July By Investing.com - Investing.com India
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $180 From $190 - Moomoo
Becton, Dickinson and Company (BDX) Stock Analysis: Evaluating Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Does Vizient’s CentroVena One Deal and Index Shuffle Change The Bull Case For Becton Dickinson (BDX)? - simplywall.st
Becton Dickinson stock gains after company lifts earnings outlook By Investing.com - Investing.com Nigeria
Becton Dickinson & Co (BDX) Stock Forum and Discussion - Moomoo
Becton Dickinson stock holds its setup. Focus shifts to business fundamentals. - AD HOC NEWS
Is It Too Late to Buy Becton Dickinson & Co (BDX) After 3.4% Ral - GuruFocus
Becton Dickinson holds steady as investors await a fresh catalyst - AD HOC NEWS
Becton, Dickinson and Company: Now Is A Great Time To Buy (NYSE:BDX) - Seeking Alpha
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System - Insider Monkey
List of 36 Acquisitions by Becton Dickinson (Jul 2026) - Tracxn
Becton Dickinson (NYSE:BDX) Advances in NYSE Composite After Vizient Deal - Kalkine Media
Becton Dickinson (BDX) Wins Vizient Contract As Fair Value Stays In Focus - simplywall.st
Becton Dickinson updates fiscal 2026 outlook, shares steady after cautious guidance - AD HOC NEWS
Form 4 Becton Dickinson and Co For: 26 June By Investing.com - Investing.com India
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Michael Feld sells $11,460 of Becton Dickinson stock - Investing.com
Becton Dickinson & Co (BDX) Stock Up 3.0% and Still Undervalued -- GF Score: 76/100 - GuruFocus
Becton Dickinson EVP sells $160,226 in BDX shares By Investing.com - Investing.com South Africa
Becton Dickinson EVP sells $160,226 in BDX shares - Investing.com UK
AQR Trend Total Return Fund's Becton Dickinson & Co(BDX) Holding History - GuruFocus
Form 4 Becton Dickinson and Co For: 25 June By Investing.com - Investing.com Australia
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):